Cybin Inc. (OTCMKTS:CYBN – Get Free Report) shares traded down 4.3% during trading on Wednesday . The stock traded as low as $10.20 and last traded at $10.25. 204,600 shares traded hands during mid-day trading, an increase of 10% from the average session volume of 186,805 shares. The stock had previously closed at $10.71.
Cybin Trading Down 4.3 %
The stock’s 50 day moving average is $10.19 and its two-hundred day moving average is $3.74. The stock has a market capitalization of $204.92 million, a price-to-earnings ratio of -1.54 and a beta of 0.38.
Cybin Company Profile
Cybin Inc, a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in Phase 1/2a clinical trial to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine, which is in Phase 1 clinical trial for treating generalized anxiety disorders; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation.
Further Reading
- Five stocks we like better than Cybin
- The Basics of Support and Resistance
- The Latest 13F Filings Are In: See Where Big Money Is Flowing
- What is the FTSE 100 index?
- 3 Penny Stocks Ready to Break Out in 2025
- 10 Best Airline Stocks to Buy
- FMC, Mosaic, Nutrien: Top Agricultural Stocks With Big Potential
Receive News & Ratings for Cybin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cybin and related companies with MarketBeat.com's FREE daily email newsletter.
